A systematic assessment of the reporting quality of randomized controlled trials of surgical interventions for nephrolithiasis (2002−2023)
DOI:
https://doi.org/10.5489/cuaj.9727Keywords:
Nephrolithiasis, Randomized Controlled Trials, CONSORT Statement, Research ReportAbstract
Introduction: We aimed to evaluate the reporting quality of randomized controlled trials (RCTs) for surgical interventions in stone disease across 2002–2023, extending two earlier reviews of the literature with a new 2018–2023 cohort. Previous assessments of the reporting quality of RCTs in nephrolithiasis have shown suboptimal adherence.
Methods: Building on two prior studies, we conducted a comprehensive literature search for RCTs assessing surgical stone interventions. Four independent reviewers performed data abstraction in duplicate. Reporting quality was assessed using the 25-item Consolidated Standards of Reporting Trials (CONSORT) checklist, with each study scored from 0−25; the primary outcome was the mean score. Scores were compared across four time periods (2002–2006, 2007−2011, 2012–2017, and 2018–2023) using ANOVA in SPSS version 29.
Results: Three hundred and thirty-one studies met inclusion criteria (2002−2006: 38, 2007−2011: 64, 2012−2017: 101, and 2018−2023: 128). The mean ± standard deviation CONSORT summary scores for the four time periods were 11.4±2.3, 12.1±2.4, 12.7±2.9, and 16.1±3.2, respectively (p<0.001). Reporting rates were lowest for reporting ancillary analyses (10.9%) and implementation of randomization (14.0%). Notable improvements over time (2002−2006 vs. 2007−2011 vs. 2012−2017 vs. 2018−2023) were seen for trial registration (0% vs. 0% vs. 13.9% vs. 40.6%, p<0.001) and funding source (5.1% vs. 9.2% vs. 13.9% vs. 62.5%, p<0.001), respectively.
Conclusions: The reporting quality of RCTs of surgical interventions for nephrolithiasis has improved, but critical methodologic domains remain underreported. Greater awareness of transparent trial reporting is needed.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.




